MAPT and Parkinson disease: In addition to tau, DYRK1A directly modifies other NDD-associated targets, including APP, presenilin-1, α-synuclein, and parkin, affecting the formation of toxic amyloid inclusions and the pathogenesis of AD and PD (33).